412 related articles for article (PubMed ID: 31781355)
1. LKB1/AMPK Pathway and Drug Response in Cancer: A Therapeutic Perspective.
Ciccarese F; Zulato E; Indraccolo S
Oxid Med Cell Longev; 2019; 2019():8730816. PubMed ID: 31781355
[TBL] [Abstract][Full Text] [Related]
2. Aurora-A-mediated phosphorylation of LKB1 compromises LKB1/AMPK signaling axis to facilitate NSCLC growth and migration.
Zheng X; Chi J; Zhi J; Zhang H; Yue D; Zhao J; Li D; Li Y; Gao M; Guo J
Oncogene; 2018 Jan; 37(4):502-511. PubMed ID: 28967900
[TBL] [Abstract][Full Text] [Related]
3. A subset of VEGFR-TKIs activates AMPK in LKB1-mutant lung cancer.
Yang L; Zhang Q; Xiong Y; Dang Z; Xiao H; Chen Q; Dai X; Zhang L; Zhu J; Wang D; Li M
Cancer Sci; 2023 Apr; 114(4):1651-1662. PubMed ID: 36459496
[TBL] [Abstract][Full Text] [Related]
4. Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells.
Memmott RM; Gills JJ; Hollingshead M; Powers MC; Chen Z; Kemp B; Kozikowski A; Dennis PA
Cancer Res; 2008 Jan; 68(2):580-8. PubMed ID: 18199555
[TBL] [Abstract][Full Text] [Related]
5. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of cervical cancer cell growth through activation of upstream kinases of AMP-activated protein kinase.
Yu SY; Chan DW; Liu VW; Ngan HY
Tumour Biol; 2009; 30(2):80-5. PubMed ID: 19407487
[TBL] [Abstract][Full Text] [Related]
7. Metformin impairs the growth of liver kinase B1-intact cervical cancer cells.
Xiao X; He Q; Lu C; Werle KD; Zhao RX; Chen J; Davis BC; Cui R; Liang J; Xu ZX
Gynecol Oncol; 2012 Oct; 127(1):249-55. PubMed ID: 22735790
[TBL] [Abstract][Full Text] [Related]
8. The AMPK-Related Kinases SIK1 and SIK3 Mediate Key Tumor-Suppressive Effects of LKB1 in NSCLC.
Hollstein PE; Eichner LJ; Brun SN; Kamireddy A; Svensson RU; Vera LI; Ross DS; Rymoff TJ; Hutchins A; Galvez HM; Williams AE; Shokhirev MN; Screaton RA; Berdeaux R; Shaw RJ
Cancer Discov; 2019 Nov; 9(11):1606-1627. PubMed ID: 31350328
[TBL] [Abstract][Full Text] [Related]
9. Oxidative stress-mediated AMPK inactivation determines the high susceptibility of LKB1-mutant NSCLC cells to glucose starvation.
Ren Y; Chen J; Chen P; Hao Q; Cheong LK; Tang M; Hong LL; Hu XY; Celestial T Yap ; Bay BH; Ling ZQ; Shen HM
Free Radic Biol Med; 2021 Apr; 166():128-139. PubMed ID: 33636336
[TBL] [Abstract][Full Text] [Related]
10. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
Han S; Khuri FR; Roman J
Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
[TBL] [Abstract][Full Text] [Related]
11. Carnosic Acid against Lung Cancer: Induction of Autophagy and Activation of Sestrin-2/LKB1/AMPK Signalling.
O'Neill EJ; Sze NSK; MacPherson REK; Tsiani E
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396629
[TBL] [Abstract][Full Text] [Related]
12. LKB1 promotes metabolic flexibility in response to energy stress.
Parker SJ; Svensson RU; Divakaruni AS; Lefebvre AE; Murphy AN; Shaw RJ; Metallo CM
Metab Eng; 2017 Sep; 43(Pt B):208-217. PubMed ID: 28034771
[TBL] [Abstract][Full Text] [Related]
13. The tumor suppressor gene TUSC2 (FUS1) sensitizes NSCLC to the AKT inhibitor MK2206 in LKB1-dependent manner.
Meng J; Majidi M; Fang B; Ji L; Bekele BN; Minna JD; Roth JA
PLoS One; 2013; 8(10):e77067. PubMed ID: 24146957
[TBL] [Abstract][Full Text] [Related]
14. Mir-451 inhibits proliferation and migration of non-small cell lung cancer cells via targeting LKB1/AMPK.
Liu Y; Li H; Li LH; Tang JB; Sheng YL
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(3 Suppl):274-280. PubMed ID: 31389598
[TBL] [Abstract][Full Text] [Related]
15. LKB1 inactivation sensitizes non-small cell lung cancer to pharmacological aggravation of ER stress.
Inge LJ; Friel JM; Richer AL; Fowler AJ; Whitsett T; Smith MA; Tran NL; Bremner RM
Cancer Lett; 2014 Oct; 352(2):187-95. PubMed ID: 25011082
[TBL] [Abstract][Full Text] [Related]
16. LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells.
Whang YM; Park SI; Trenary IA; Egnatchik RA; Fessel JP; Kaufman JM; Carbone DP; Young JD
Oncogene; 2016 Feb; 35(7):856-66. PubMed ID: 26119936
[TBL] [Abstract][Full Text] [Related]
17. Involvement of E-cadherin/AMPK/mTOR axis in LKB1-induced sensitivity of non-small cell lung cancer to gambogic acid.
Li X; Tang X; Su J; Xu G; Zhao L; Qi Q
Biochem Pharmacol; 2019 Nov; 169():113635. PubMed ID: 31513784
[TBL] [Abstract][Full Text] [Related]
18. LKB1 in lung cancerigenesis: a serine/threonine kinase as tumor suppressor.
Gao Y; Ge G; Ji H
Protein Cell; 2011 Feb; 2(2):99-107. PubMed ID: 21380642
[TBL] [Abstract][Full Text] [Related]
19. Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC.
Moro M; Caiola E; Ganzinelli M; Zulato E; Rulli E; Marabese M; Centonze G; Busico A; Pastorino U; de Braud FG; Vernieri C; Simbolo M; Bria E; Scarpa A; Indraccolo S; Broggini M; Sozzi G; Garassino MC
J Thorac Oncol; 2018 Nov; 13(11):1692-1704. PubMed ID: 30149143
[TBL] [Abstract][Full Text] [Related]
20. Tumor suppression by LKB1: SIK-ness prevents metastasis.
Shaw RJ
Sci Signal; 2009 Sep; 2(86):pe55. PubMed ID: 19724060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
